Subtlety of the structure-affinity and structure-efficacy relationships around a nonpeptide oxytocin receptor agonist.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Journal of Medicinal Chemistry

• Publication date

  2010-01-27

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/jm901084fPMID 20104850
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.

  2008cited by this paper
• Non-peptide arginine-vasopressin antagonists: the vaptans.

  2008cited by this paper
• The 2.6 Angstrom Crystal Structure of a Human A2A Adenosine Receptor Bound to an Antagonist

  2008cited by this paper
• Association of the oxytocin receptor gene (OXTR) in Caucasian children and adolescents with autism.

  2007cited by this paper
• Blood-brain barrier delivery.

  2007cited by this paper
• Nonpeptidic ligands for peptide-activated G protein-coupled receptors.

  2007cited by this paper
• Substituted NDP-MSH peptides paired with mutant melanocortin-4 receptors demonstrate the role of transmembrane 6 in receptor activation.

  2007cited by this paper
• Molecular Interaction of a Potent Nonpeptide Agonist with the Chemokine Receptor CCR8

  2007cited by this paper
• Systematic analysis of the entire second extracellular loop of the V(1a) vasopressin receptor: key residues, conserved throughout a G-protein-coupled receptor family, identified.

  2007cited by this paper
• The neurobiology of love

  2007cited by this paper
• Oxytocin increases retention of social cognition in autism.

  2007cited by this paper
• From affiliative behaviors to romantic feelings: A role of nanopeptides

  2007cited by this paper
• Mapping the binding site of arginine vasopressin to V1a and V1b vasopressin receptors.

  2007cited by this paper
• Multiple Residues in the Second Extracellular Loop Are Critical for M3 Muscarinic Acetylcholine Receptor Activation*

  2007cited by this paper
• Small Molecule Receptor Agonists and Antagonists of CCR3 Provide Insight into Mechanisms of Chemokine Receptor Activation*

  2007cited by this paper
• Identification of an Efficacy Switch Region in the Ghrelin Receptor Responsible for Interchange between Agonism and Inverse Agonism*

  2007cited by this paper
• 3-Dimensional structures of G protein-coupled receptors and binding sites of agonists and antagonists.

  2007cited by this paper
• Partial Agonism, Neutral Antagonism, and Inverse Agonism at the Human Wild-Type and Constitutively Active Cholecystokinin-2 Receptors

  2006cited by this paper
• Novel benzodiazepine photoaffinity probe stereoselectively labels a site deep within the membrane-spanning domain of the cholecystokinin receptor.

  2006cited by this paper
• Charged Extracellular Residues, Conserved throughout a G-protein-coupled Receptor Family, Are Required for Ligand Binding, Receptor Activation, and Cell-surface Expression*

  2006cited by this paper
• F200A substitution in the third transmembrane helix of human cannabinoid CB1 receptor converts AM2233 from receptor agonist to inverse agonist.

  2006cited by this paper
• Molecular mechanism of 7TM receptor activation--a global toggle switch model.

  2006cited by this paper
• Mapping the Binding Site of Six Nonpeptide Antagonists to the Human V2-Renal Vasopressin Receptor

  2006cited by this paper
• Pyridobenzodiazepines: a novel class of orally active, vasopressin V2 receptor selective agonists.

  2006cited by this paper
• Disulfide trapping to localize small-molecule agonists and antagonists for a G protein-coupled receptor.

  2005cited by this paper
• Positive association of the oxytocin receptor gene (OXTR) with autism in the Chinese Han population.

  2005cited by this paper
• Oxytocin increases trust in humans

  2005cited by this paper
• Oxytocin is associated with human trustworthiness.

  2005cited by this paper
• Binding domains of the oxytocin receptor for the selective oxytocin receptor antagonist barusiban in comparison to the agonists oxytocin and carbetocin.

  2005cited by this paper
• Molecular interactions of nonpeptide agonists and antagonists with the melanocortin-4 receptor.

  2005cited by this paper
• Molecular Characterization of a Purified 5-HT4 Receptor

  2005cited by this paper
• Principles: a model for the allosteric interactions between ligand binding sites within a dimeric GPCR.

  2005cited by this paper
• Key amino acids located within the transmembrane domains 5 and 7 account for the pharmacological specificity of the human V1b vasopressin receptor.

  2004cited by this paper
• Non-peptide oxytocin agonists.

  2004cited by this paper
• High-Throughput Modeling of Human G-Protein Coupled Receptors: Amino Acid Sequence Alignment, Three-Dimensional Model Building, and Receptor Library Screening

  2004cited by this paper
• The Neurobiology of Trust

  2004cited by this paper
• Social modulation of stress responses.

  2003cited by this paper
• Identification of the Binding Sites of the SR49059 Nonpeptide Antagonist into the V1a Vasopressin Receptor Using Sulfydryl-reactive Ligands and Cysteine Mutants as Chemical Sensors*

  2003cited by this paper
• Social support and oxytocin interact to suppress cortisol and subjective responses to psychosocial stress.

  2003cited by this paper
• Oxytocin Infusion Reduces Repetitive Behaviors in Adults with Autistic and Asperger's Disorders

  2003cited by this paper
• Improved protein–ligand docking using GOLD

  2003cited by this paper
• An arginyl in the N-terminus of the V1a vasopressin receptor is part of the conformational switch controlling activation by agonist.

  2003cited by this paper
• Modeling the adenosine receptors: comparison of the binding domains of A2A agonists and antagonists.

  2003cited by this paper
• A single residue (arg46) located within the N-terminus of the V1a vasopressin receptor is critical for binding vasopressin but not peptide or nonpeptide antagonists.

  2002cited by this paper
• Characterization of orally active nonpeptide vasopressin V(2) receptor agonist. Synthesis and biological evaluation of both the (5R)- and (5S)-enantioisomers of 2-[1-(2-Chloro-4-pyrrolidin-1-yl-benzoyl)-2,3,4,5-tetrahydro-1H-1-benzazepin- 5-yl]-N-isopropylacetamide.

  2002cited by this paper
• Molecular pharmacology and modeling of vasopressin receptors.

  2002cited by this paper
• Agonist-specific, high-affinity binding epitopes are contributed by an arginine in the N-terminus of the human oxytocin receptor.

  2002cited by this paper
• Transmission disequilibrium testing of arginine vasopressin receptor 1A (AVPR1A) polymorphisms in autism

  2002cited by this paper
• The Biologically Crucial C Terminus of Cholecystokinin and the Non-peptide Agonist SR-146,131 Share a Common Binding Site in the Human CCK1 Receptor

  2002cited by this paper
• Protein‐based virtual screening of chemical databases. II. Are homology models of g‐protein coupled receptors suitable targets?

  2002cited by this paper
• Oxytocin and autistic disorder: alterations in peptide forms.

  2001cited by this paper
• The neurobiology of attachment

  2001cited by this paper
• Functionally Different Agonists Induce Distinct Conformations in the G Protein Coupling Domain of the β2Adrenergic Receptor*

  2001cited by this paper
• Direct Identification of Human Oxytocin Receptor-binding Domains Using a Photoactivatable Cyclic Peptide Antagonist

  2001cited by this paper
• Peptide-binding G protein-coupled receptors: new opportunities for drug design.

  2001cited by this paper
• Characterization of a novel nonpeptide vasopressin V2‐agonist, OPC‐51803, in cells transfected human vasopressin receptor subtypes

  2000cited by this paper
• Crystal structure of rhodopsin: A G protein-coupled receptor.

  2000cited by this paper
• Novel design of nonpeptide AVP V(2) receptor agonists: structural requirements for an agonist having 1-(4-aminobenzoyl)-2,3,4, 5-tetrahydro-1H-1-benzazepine as a template.

  2000cited by this paper
• The agonist SR 146131 and the antagonist SR 27897 occupy different sites on the human CCK(1) receptor.

  2000cited by this paper
• Conserved aromatic residues in the transmembrane region VI of the V1a vasopressin receptor differentiate agonist vs. antagonist ligand binding.

  2000cited by this paper
• Functional architecture of vasopressin/oxytocin receptors.

  1999cited by this paper
• Oxytocin, vasopressin, and autism: is there a connection?

  1999cited by this paper
• Docking of linear peptide antagonists into the human V(1a) vasopressin receptor. Identification of binding domains by photoaffinity labeling.

  1999cited by this paper
• Neuroendocrine perspectives on social attachment and love.

  1998cited by this paper
• Love: an emergent property of the mammalian autonomic nervous system.

  1998cited by this paper
• Love as sensory stimulation: physiological consequences of its deprivation and expression.

  1998cited by this paper
• Structural bases of vasopressin/oxytocin receptor function.

  1998cited by this paper
• Plasma oxytocin levels in autistic children.

  1998cited by this paper
• Oxytocin may mediate the benefits of positive social interaction and emotions.

  1998cited by this paper
• Development of orally active oxytocin antagonists: studies on 1-(1-[4-[1-(2-methyl-1-oxidopyridin-3-ylmethyl)piperidin-4-yloxy]-2- methoxybenzoyl]piperidin-4-yl)-1,4-dihydrobenz[d][1,3]oxazin-2-one (L-372,662) and related pyridines.

  1998cited by this paper
• Pharmacological characterization of a nonpeptide bradykinin B2 receptor antagonist, FR165649, and agonist, FR190997

  1998cited by this paper
• Dual agonistic and antagonistic property of nonpeptide angiotensin AT1 ligands: susceptibility to receptor mutations.

  1997cited by this paper
• Efficient photoaffinity labeling of the rat V1a vasopressin receptor using a linear azidopeptidic antagonist.

  1997cited by this paper
• Mapping Peptide-binding Domains of the Human V1a Vasopressin Receptor with a Photoactivatable Linear Peptide Antagonist*

  1997cited by this paper
• Nonpeptide arginine vasopressin antagonists for both V1A and V2 receptors: synthesis and pharmacological properties of 2-phenyl-4'-[(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]benzanil ide derivatives.

  1997cited by this paper
• Orally active, nonpeptide vasopressin V2 receptor antagonists: a novel series of 1-[4-(benzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-benzazepines and related compounds.

  1996cited by this paper
• Two aromatic residues regulate the response of the human oxytocin receptor to the partial agonist arginine vasopressin

  1996cited by this paper
• Separate Agonist and Peptide Antagonist Binding Sites of the Oxytocin Receptor Defined by Their Transfer into the V2 Vasopressin Receptor*

  1996cited by this paper
• Crystal structure of the neurophysin—oxytocin complex

  1996cited by this paper
• Discovery of 1,5-benzodiazepines with peripheral cholecystokinin (CCK-A) receptor agonist activity. 1. Optimization of the agonist "trigger".

  1996cited by this paper
• The Binding Site of Neuropeptide Vasopressin V1a Receptor

  1995cited by this paper
• 1-(1-[4-[(N-acetyl-4-piperidinyl)oxy]-2-methoxybenzoyl]piperidin-4- yl)-4H-3,1-benzoxazin-2(1H)-one (L-371,257): a new, orally bioavailable, non-peptide oxytocin antagonist.

  1995cited by this paper
• Tyr115 is the key residue for determining agonist selectivity in the V1a vasopressin receptor.

  1995cited by this paper
• An extracellular residue determines the agonist specificity of V2 vasopressin receptors

  1995cited by this paper
• CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice.

  1994cited by this paper
• Direct identification of an extracellular agonist binding site in the renal V2 vasopressin receptor.

  1993cited by this paper
• OPC-21268, an orally effective, nonpeptide vasopressin V1 receptor antagonist.

  1991cited by this paper
• Bimorphinans as highly selective, potent kappa opioid receptor antagonists.

  1987cited by this paper
• [Studies on substances with antitumor activity. XXXVI. Anthramycin and similar compounds. I. Synthesis of 10,11-diidro-5H-pyrrole-(2,1-c)(1,4)-benzodiazepine].

  1969cited by this paper
• [A molecular basis for the action of drugs. I. Receptor-theory and structure-effect relations].

  1966cited by this paper

• Intrathecal injections of non-peptide oxytocin receptor agonists, WAY 267,464 and TC OT 39, induce significant anti-hyperalgesia in both male and female rats with inflammatory pain

  2025cites this paper
• Elucidating and Optimizing the Photochemical Mechanism of Coumarin-Caged Tertiary Amines

  2024cites this paper
• Pharmacological chaperones for the oxytocin receptor increase oxytocin responsiveness in myometrial cells

  2022cites this paper
• [Oxytocin and its receptor: molecular and therapeutic approaches].

  2022cites this paper
• Benzodiazepine Derivatives as Potent Vasopressin V2 Receptor Antagonists for the Treatment of Autosomal Dominant Kidney Disease.

  2022cites this paper
• The Current Status of Drug Discovery for the Oxytocin Receptor.

  2021cites this paper
• Oxytocin-System | Encyclopedia

  2020cites this paper
• Hypothalamic Neuropeptide Brain Protection: Focus on Oxytocin

  2020cites this paper
• The Reaction of o ‐Aminoacetophenone N ‐Tosylhydrazone and CO 2 toward 1,4‐Dihydro‐2 H ‐3,1‐benzoxazin‐2‐ones

  2019cites this paper
• Prosocial effects of an oxytocin metabolite, but not synthetic oxytocin receptor agonists, in a mouse model of autism

  2019cites this paper
• LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism.

  2018cites this paper
• Molecular Basis of Oxytocin Receptor Signalling in the Brain: What We Know and What We Need to Know.

  2018cites this paper
• Standard Curves Are Necessary to Determine Pharmacological Properties for Ligands in Functional Assays Using Competition Binding Technologies

  2017cites this paper
• Targets for Drug Therapy for Autism Spectrum Disorder: Challenges and Future Directions.

  2017cites this paper
• The Formation of Seven-Membered Heterocycles under Mild Pictet-Spengler Conditions: A Route to Pyrazolo[3,4]benzodiazepines.

  2016cites this paper
• Flexible analogues of WAY-267,464: Synthesis and pharmacology at the human oxytocin and vasopressin 1a receptors.

  2016cites this paper
• Selective nonpeptidic fluorescent ligands for oxytocin receptor: design, synthesis, and application to time-resolved FRET binding assay.

  2015cites this paper
• [Oxytocin model of formation of psychotic symptoms and its implications for research on oxytocinergic pathway in schizophrenia].

  2014cites this paper
• Pyrazolo[1,4]diazepines as non-peptidic probes of the oxytocin and vasopressin receptors

  2014cites this paper
• Oxytocin and Vasopressin Agonists and Antagonists as Research Tools and Potential Therapeutics

  2012cites this paper
• Agonist-specific requirement for a glutamate in transmembrane helix 1 of the oxytocin receptor.

  2011cites this paper
• Identification of Nonpeptide Oxytocin Receptor Ligands by Receptor‐Ligand Fingerprint Similarity Search

  2011cites this paper